Evidentic • Therapeutic Indications • Chronic lymphocytic leukaemia and Rheumatoid arthritis
The association between chronic lymphocytic leukaemia and rheumatoid arthritis has been confirmed in some cases. Rheumatoid arthritis is a chronic autoimmune inflammatory disease characterized by erosive arthritis of the joints.
Chronic lymphocytic leukaemia is a clonal malignancy of lymphocytes, which is manifested by immunosuppression, bone marrow failure, and organ infiltration with neoplastic cells.
Showing all 8 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price | |
---|---|---|---|---|---|---|---|---|---|---|
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
09/2018 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2018 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
02/2019 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
02/2019 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
08/2019 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2019 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
07/2021 |
250,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
yes |
2 mg |
2-8°C / -80°C |
02/2023 |
217,00Â € |
Let us know about your inquiry details and we’ll contact you shortly.